Alpine BioVentures
600 Stewart Street Suite 1503, Seattle, WA, 98101, United States
Overview
Alpine BioVentures, GP, LLC is providing this website for informational purposes only. Nothing on this website is intended to constitute, or should be deemed to be, financial advisory, legal, tax, accounting or other professional advice to you or any other party; be an opinion of the appropriateness or suitability of any investment; or constitute an offer to sell or solicitation of an offer to buy any security or investment. This website and its content (collectively, “Content”) is intended for general informational purposes only and should not be acted upon without first obtaining financial advisory, legal, tax, accounting or other professional advice from your consultant or other professional with respect to your own personal investment objectives, financial circumstances and needs.
- Total investments
- 3
- Lead investments
- 1
- Investments · 12mo
- 0
- Active investors
- 0
Sector focus
- Finance
- Venture Capital
Investment portfolio
- Mavupharma
Participated · Series A · Nov 2017
Mavupharma is a Kirkland, Wash.-based drug discovery and development company focused on orally bioavailable, non-nucleotide modulators of the STING (stimulator of interferon genes) pathway. The company is led by Michael Gallatin, Ph.D., president, and Greg Dietsch, Ph.D. Mavupharma aims to develop therapies to treat cancer and infectious diseases using its STING-targeting small molecules. It secured new capital to advance its programs and intends to use the funds to move its lead drug candidates into the clinic. As part of its corporate leadership changes tied to the financing, Bob Baltera of Cirius Therapeutics will join as executive chairman. Financial details reported indicate the company completed a Series A financing to support these near-term clinical plans.
- Alpine Immune Sciences
Participated · Series A · Jun 2016
Alpine Immune Sciences focuses on developing novel protein-based immunotherapies built on its proprietary vIgD™ platform, which is designed to interact with multiple immune targets simultaneously at the immune synapse. The company uses directed evolution of naturally occurring ligands to create vIgD™ molecules that can either enhance or diminish immune responses, making the technology applicable to both cancer and autoimmune indications. AIS has also developed transmembrane immunomodulatory protein (TIP™) technology, derived from the vIgD™ platform, for use with engineered cellular therapies to potentially improve efficacy and persistence. In October 2015 AIS signed a worldwide research and license agreement with Kite Pharma worth up to $530 million granting Kite access to certain targets developed using the TIP™ platform. AIS was founded in 2015 and was seed funded by Alpine BioVentures. The company recently completed a $48 million Series A to support continued discovery and development of its immunotherapy programs. Alpine Immune Sciences is a stealth immunotherapy company pursuing a recombinant protein–based therapeutic platform that the founders say is unrelated to Dendreon’s Provenge. The company was seeded with about $1.3 million provided through Mitchell Gold’s investment firm, Alpine BioVentures. SEC filings list former Amgen scientists Michael Kornacker and Ryan Swanson as participants; both appear to have left their Amgen positions in December. Kornacker’s background is in antibody protein engineering, while Swanson’s work focuses on inflammation and T‑cell stimulation. David Miller, who also heads Alpine BioVentures, is listed as running Alpine Immune Sciences and works as a portfolio manager. The team is keeping product and operational details confidential while the startup remains in stealth.
Team
No current team members are available.